Navigation Links
Rhode Island Hospital fellow receives funding to support research in myocardial perfusion
Date:6/7/2011

(Providence, R.I.) Antonio Lassaletta, M.D., a fellow in cardiothoracic surgery research at Rhode Island Hospital, has been awarded a Research Fellowship from the Thoracic Surgery Foundation for Research and Education (TSFRE) to support his project, "Improving Myocardial Perfusion in a Diabetic Swine Model of Chronic Cardiac Ischemia." TSFRE awarded just two Research Fellowships in 2011; Lassaletta's fellowship is for two years.

TSFRE fellowships are designed to provide salary and/or direct experimental support for surgeons and surgical trainees who wish to acquire research skills. Particular emphasis is placed on evidence of supervisory interaction in the training environment. Lassaletta's research is being conducted under the guidance of Frank Sellke, M.D., chief of cardiothoracic surgery at Rhode Island Hospital and The Miriam Hospital. Sellke is nationally and internationally recognized for his clinical skills, commitment to excellence in patient care, and seminal and cutting-edge National Institutes of Health-supported cardiovascular research.

"Dr. Lassaletta has demonstrated a strong commitment to cardiothoracic care," said Sellke. "His work ethic and dedication to furthering patient care through research findings is commendable, and this fellowship is greatly deserved. The TSFRE is very selective in determining the recipients of these fellowships, and I am encouraged by their support of Dr. Lassaletta and his work."

Lassaletta's research measures the changes in blood supply to the heart in swine in order to investigate the effects of regenerative medicine. His goal is to determine if swine with Type I diabetes, suffering from reduced blood flow to the heart possibly brought on by coronary artery disease, will show improvement after the subjects receive a surgically implanted pump that encourages blood vessel growth in the heart, and that these improvements will be sustained with the addition of resveratrol. Resveratrol is a widely used FDA-unregulated supplement that has shown improved blood flow to the heart in humans.

The purpose of The Thoracic Surgery Foundation for Research and Education is to increase the knowledge base of cardiothoracic surgery and to enhance the knowledge of all thoracic surgeons so that ultimately patients may be better served. The TSFRE is committed to increasing resources by enlisting the participation of all thoracic surgeons and others who support its purpose. The Thoracic Surgery Foundation for Research and Education supports research and education initiatives to:

  • Increase knowledge and enhance treatment of patients with cardiothoracic diseases
  • Develop the skills of cardiothoracic surgeons as surgeon-scientists and health policy leaders
  • Strengthen society's understanding and trust in the profession


'/>"/>

Contact: Ellen Slingsby
eslingsby@lifespan.org
401-444-6421
Lifespan
Source:Eurekalert

Related medicine news :

1. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
2. Rhode Island Hospital physician receives national award for research
3. Women & Infants launches Rhode Island Network for Pelvic Floor Disorders
4. Paper by Rhode Island Hospital physician selected among best of 2010 by JACR
5. Tishman Speyer Hosts Government, Union and Civic Leaders for Topping Out of Gotham Center Tower in Long Island City
6. Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers
7. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
8. Long Island Children's Orthodontist Announces Office Improvements And New Staff Member
9. New Aspen Dental Office Opens in Grand Island, Nebraska
10. Relevant Public Relations President Barton Horowitz of Staten Island, N.Y., Chamber CEO Linda Baran Applauded By Congressman McMahon as SBA Honorees
11. Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... Only two months after the official release of The Private Collection ... XO Private has initiated a second print-run of its lavish luxury travel coffee table ... when open, weighs in at more than six kilos, retails at EUR 1,000 per ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology: